title: Requiring institutions to inform participants who have completed therapy on SWOG-8892 (RT +/- cisplatin for nasopharyngeal cancer) about early study closure: right idea, wrong patients.
authors.forename: R J
authors.initials: RJ
authors.lastname: Amdur
authors.forename: E
authors.initials: E
authors.lastname: Bankert
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic / Q000331:legislation & jurisprudence* / Q000592:standards; D003131:Combined Modality Therapy; D006801:Humans; D015337:Multicenter Studies as Topic / Q000331:legislation & jurisprudence* / Q000592:standards; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D010349:Patient Compliance; D011367:Professional Staff Committees / Q000331:legislation & jurisprudence* / Q000592:standards; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D014342:Truth Disclosure; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D002945:Cisplatin